Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy

Abstract

Constant drug release from paclitaxel gelatin nanoparticles may overcome the problem of drug dilution by newly produced urine and the sustained drug levels in tumors may decrease treatment frequency.